Investment
Features
FeesSafety
Academy
More
Pluang+

Astera Labs posts Q2 revenue of $392.4M, up 104% YoY, driven by AI fabric growth and Scorpio switch ramp.

Company Fundamentals
04 Aug 2026
GlobeNewsWire
View Source
Bullish
Astera Labs posts Q2 revenue of $392.4M, up 104% YoY, driven by AI fabric growth and Scorpio switch ramp.

Astera Labs reported a record Q2 2026 revenue of $392.4 million, a 27% increase from the previous quarter and 104% year-over-year growth, fueled by strong demand in AI fabrics and signal conditioning products. The company highlighted the upcoming production ramp of its Scorpio X-Series 320-lane fabric switch, expected to drive further revenue growth in Q3. Astera Labs is expanding its product portfolio and global presence, positioning itself as a comprehensive AI fabric infrastructure provider with new design wins and partnerships. The company projects Q3 revenue between $540 million and $560 million, with continued margin strength and profitability.

More News

THOR Industries misses Q4 EPS estimates but beats revenue expectations amid RV market challenges

THOR Industries misses Q4 EPS estimates but beats revenue expectations amid RV market challenges

THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...

Company Fundamentals
Bearish
1 hour ago
Cracker Barrel earnings expected to drop sharply in Q3 2026, with EPS forecast at $0.17 and revenue down.

Cracker Barrel earnings expected to drop sharply in Q3 2026, with EPS forecast at $0.17 and revenue down.

Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...

Company Fundamentals
Bearish
1 hour ago
Abivax gains FDA nod for Obefazimod, backed by strong cash and positive analyst outlook.

Abivax gains FDA nod for Obefazimod, backed by strong cash and positive analyst outlook.

Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...

Market News
Bullish
2 hours ago
Netflix stock downgraded by HSBC and Wells Fargo over falling viewer engagement.

Netflix stock downgraded by HSBC and Wells Fargo over falling viewer engagement.

HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...

Market News
Bearish
2 hours ago
FormFactor director sells 2,100 shares, signaling insider stock movement

FormFactor director sells 2,100 shares, signaling insider stock movement

A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...

Market News
Bearish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App